Healio

Subcutaneous testosterone therapy safe, effective in female-to-male transgender patients

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In female-to-male transgender patients, ...
Medscape

FDA Clears First Autoinjectable Testosterone, Xyosted

The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...
Healio

Subcutaneous testosterone effective HT for transgender male, gender-diverse youths

Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...
Business Wire

Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...
Pharmabiz

Antares Pharma reports positive results from phase II Vibex QuickShot pharmacokinetic study in testosterone deficient adult males

Antares Pharma, Inc. has reported positive results from a multi-centre phase II clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...
Medscape

Degarelix 240/80 mg: A New Treatment Option for Patients with Advanced Prostate Cancer

Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...